| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INBX | Stock Option (right to buy) | Disposed to Issuer | -3.5K | -100% | 0 | May 30, 2024 | Common Stock | 3.5K | $17.44 | Direct | F1, F2, F3 | ||
| transaction | INBX | Stock Option (right to buy) | Disposed to Issuer | -15K | -100% | 0 | May 30, 2024 | Common Stock | 15K | $23.03 | Direct | F1, F3, F4 | ||
| transaction | INBX | Stock Option (right to buy) | Disposed to Issuer | -15K | -100% | 0 | May 30, 2024 | Common Stock | 15K | $12.57 | Direct | F1, F3, F5 | ||
| transaction | INBX | Stock Option (right to buy) | Disposed to Issuer | -15K | -100% | 0 | May 30, 2024 | Common Stock | 15K | $24.78 | Direct | F1, F3, F6 | ||
| transaction | INBX | Stock Option (right to buy) | Disposed to Issuer | -17.3K | -100% | 0 | May 30, 2024 | Common Stock | 17.3K | $20.43 | Direct | F1, F3, F7 |
Kimberly Manhard is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). |
| F2 | Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on October 2, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| F3 | This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such stock option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. |
| F4 | Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| F5 | Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| F6 | Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| F7 | Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 23, 2021, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |